|
|
|
| A Study of the Curative Effect of Entecavir and Tongluo Ruanjian Capsule for Patients with Posthepatitic Cirrhosis and Their Effect on Liver Function and Liver Fibrosis |
| SHEN Lixian, WANG Xiaoling, LI Huiwen |
| Hebei Hepatopathy Hospital of Traditional Chinese Medicine, Hebei Shijiazhuang 050800, China |
|
|
|
|
Abstract Objective: To explore the clinical effect of entecavir and Tongluo Ruanjian capsule in the treatment of liver fibrosis after hepatitis B, and to observe the influence of entecavir and Tongluo Ruanjian Capsule on serum indexes, liver function and liver fibrosis. Methods: From January 2015 to January 2017, 120 patients with liver fibrosis after hepatitis B were collected as the study object, and divided into control group and observation group with simple random number table method, 60 cases in each group. Both groups were given basic treatment, including vitamin, diammonium glycyrrhizinate enteric coated capsules, etc. On this basis, the patients in the control group were additionally administered with entecavir tablets; the patients in the observation group were additionally administered with Tongluo Ruanjian capsule. Both groups were treated for 6 months and 2 courses. The changes of serum matrix metalloproteinase-13 (MMP-13), tumor necrosis factor α (TNF - α), transforming growth factor β 1 (TGF - β 1), international standard ratio (INR) and end-stage liver disease model score (MELD) were observed and evaluated before and after treatment. The changes of liver function indexes and liver fibrosis indexes were compared before and after treatment. The clinical efficacy and adverse reactions of the two groups were observed and recorded, and the safety of the two groups was evaluated. Results: After two courses of treatment, the total effective rate of clinical treatment in the observation group was 95.00% (57 / 60), significantly higher than 81.67% (49 / 60) in the control group, and the difference was statistically significant (P < 0.01). The serum inflammatory indexes (MMP-13, TNF - α, TGF - β 1), liver function indexes (ALT, GGT, TB), INR and MELD scores in the two groups were significantly lower than those before treatment, and the improvement degree of each index in the observation group was more significant than that in the control group, with statistical significance (P < 0.01). The index of liver fibrosis in the observation group was significantly lower than that in the control group (P < 0.01). During the treatment, no serious adverse reactions were found in the two groups. Conclusion: Entecavir tablet combined with Tongluo Ruanjian capsule has obvious curative effect for patients with liver fibrosis after hepatitis B, which can significantly improve the liver function and liver fibrosis index, and it is safe.
|
|
|
|
|
|
[1] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南(2019年版)[J].临床肝胆病杂志,2019,35(7):1444~1449.
[2] 李以军.肝纤维化诊疗研究进展[J].中国民族民间医药,2019,28(9):48~53.
[3] 谢晓.乙型肝炎肝硬化抗病毒治疗的进展[J].实用肝脏病杂志,2018,21(1):140~144.
[4] 张学伟,石炜,殷晓飞,等.胸腺肽注射液联合恩替卡韦治疗对肝硬化代偿期患者病毒负荷、肝纤维化、免疫应答的影响[J].海南医学院学报,2017,23(20):2779~2782.
[5] 中华中医药学会肝胆病专业委员会,中国民族医药学会肝病专业委员会.慢性乙型肝炎中医诊疗指南(2018年版)[J].中西医结合肝病杂志,2019,29(1):97~102.
[6] 郑虹,肖海,吴雄健.肝纤维化的发病机制及治疗的最新进展[J].赣南医学院学报,2019,39(3):298~302,308.
[7] 张海涛,张雨晴.复方鳖甲软肝片对乙肝肝纤维化患者疗效及血清TGF-β1、TNF-α、IL-6水平的影响[J].山东医药,2017,57(34):36~38.
[8] 禤传凤,罗伟生,陈国忠,等.中药活性成分干预肝纤维化分子信号通路的研究进展[J].中国药理学通报,2017,33(12):1638~1641.
[9] 郭津生.肝纤维化研究热点及进展-2019年视点[J].中华肝脏病杂志,2019,27(6):401~402.
[10] 段红岩.微生态制剂联合抗病毒治疗对乙肝肝硬化患者免疫功能及肝纤维化指标的影响[J].河北医学,2019,25(11):1861~1865.
[11] 王琪.恩替卡韦联合长效干扰素治疗乙肝的临床效果分析[J].临床医药文献电子杂志,2019,6(38):45.
[12] 刘劲松.乙肝后肝硬化采用复方鳖甲软肝片联合恩替卡韦治疗临床疗效观察[J].健康之路,2018,17(4):28.
[13] 孙钧,柴玲霞,孙逸来.关于乙型肝炎瘀血阻络证临床研究中涉及的几个关键问题[J].中医研究,2017,30(1):9~10. |
|
|
|
2020, Vol. 26 
